ASCO issues new PCO in treatment of chemotherapy-naive CRPC

ASCO has just released a new set of provisional guidance (a “provisional clinical opinion” or PCO) on the second-line treatment of men with chemotherapy-naive, castration-resistant prostate cancer (CRPC), i.e., men who are progressing on initial androgen deprivation therapy (ADT or “hormone” therapy) but who haven’t had docetaxel-based chemotherapy yet. … READ MORE …

Minnelide: a possible new drug for the treatment of CRPC?

According to a recently published article in The Prostate, researchers at the University of Minnesota have developed a new type of drug that they believe may have high therapeutic potential in the treatment of castration-resistant prostate cancer (CRPC). … READ MORE …

No sign of evident clinical benefit in the Phase IV PLATO trial

According to a recent media release, there was no significant benefit for the investigational combination of enzalutamide (Xtandi) + abiraterone acetate (Zytiga) + prednisone in treatment of men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (cnmCRPC). … READ MORE …

Abiraterone acetate + dutasteride in treatment of mCRPC

Does adding dutasteride (Avodart) to abiraterone acetate (Zytiga) make any difference in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC)? There is no clear answer to this question from a small, Phase II, pilot study, the results of which have just been published in Clinical Cancer Research. … READ MORE …

Another new biotech company to be focused on treatments for CRPC

Rumor reaches us that another new biotech company, called Fortis Therapeutics, is to be focused (at least initially) on possible new forms of treatment for late stage prostate cancer. … READ MORE …

Living with very advanced forms of prostate cancer

A new article in the journal Supportive Care in Cancer makes the point that informational needs and resources for men dealing with metastatic, castration-resistant prostate cancer continue to be relatively poor — a fact that we would not disagree with. … READ MORE …

Everolimus + bicalutamide in treatment of CRPC?

A small, single-institution, Phase II clinical trial has suggested the possibility that everolimus + bicalutamide may have useful activity in the treatment of some men with castration-resistant prostate cancer. … READ MORE …